STAP-2 Inhibitors
STAP-2 Inhibitors are a class of compounds that can directly or indirectly decrease the functional activity of STAP-2. These inhibitors primarily act through inhibiting specific signaling pathways or cellular processes in which STAP-2 is directly involved. Y-27632, a Rho-associated protein kinase (ROCK) inhibitor, inhibits RhoA, which interacts with STAP-2. By inhibiting this pathway, Y-27632 can indirectly lead to decreased STAP-2 activity. SB203580 and SP600125 are p38 MAPK and JNK inhibitors, respectively. As STAP-2 is involved in MAPK and JNK signaling pathways, the inhibition of these pathways can result in the decreased activity of STAP-2.
Furthermore, compounds like LY294002 and Wortmannin are PI3K inhibitors. As STAP-2 acts downstream of PI3K in the signaling pathway, inhibiting PI3K can logically lead to the decreased activity of STAP-2. BAY 11-7082 and JSH-23 are NF-κB pathway inhibitors. Since STAP-2 can interact with the NF-κB pathway, inhibition of this pathway can lead to decreased STAP-2 activity. Additionally, U0126, PD98059, Selumetinib, and Trametinib are MEK inhibitors. As STAP-2 is involved in the MEK/ERK signaling pathway, the inhibition of MEK canindirectly decrease the activity of STAP-2. Rapamycin, an mTOR inhibitor, can also decrease STAP-2 activity, given that mTOR is upstream of STAP-2 in the PI3K/AKT/mTOR pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a Rho-associated protein kinase (ROCK) inhibitor. It is known to inhibit RhoA, which interacts with STAP-2. By inhibiting this pathway, Y-27632 can indirectly lead to decreased STAP-2 activity. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB203580 is a p38 MAPK inhibitor. As STAP-2 is involved in MAPK signaling pathways, the inhibition of p38 MAPK can potentially result in the decreased activity of STAP-2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. It can potentially decrease STAP-2 activity, as it is involved in the JNK signaling pathway. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an NF-κB pathway inhibitor. Since STAP-2 can interact with the NF-κB pathway, inhibition of this pathway can potentially lead to decreased STAP-2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. By inhibiting MEK, it can potentially lead to the decreased activity of STAP-2, given its involvement in the MEK/ERK signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. mTOR is upstream of STAP-2 in the PI3K/AKT/mTOR pathway, and inhibition of this pathway can potentially decrease STAP-2 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor. Inhibiting PI3K, which is upstream of STAP-2 in the signaling pathway, can logically lead to the decreased activity of STAP-2. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
JSH-23 is an NF-κB inhibitor that prevents its nuclear translocation. Since STAP-2 can interact with the NF-κB pathway, inhibition of this pathway can potentially lead to decreased STAP-2 activity. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a MEK inhibitor. Given STAP-2's involvement in the MEK/ERK signaling pathway, the inhibition of MEK can indirectly decrease the activity of STAP-2. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor. By inhibiting MEK, it can potentially lead to the decreased activity of STAP-2, given its involvement in the MEK/ERK signaling pathway. | ||||||